Literature DB >> 23959776

Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis.

Giorgio Treglia, Vahid Reza Dabbagh Kakhki, Luca Giovanella, Ramin Sadeghi.   

Abstract

BACKGROUND: Some studies reported the usefulness of fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in patients with Merkel cell carcinoma (MCC).
OBJECTIVE: The aim of this study was to systematically review and meta-analyze published data about the diagnostic performance of 18F-FDG PET and PET/CT in patients with MCC.
METHODS: A comprehensive literature search of studies published through June 2013 regarding 18F-FDG PET and PET/CT in patients with MCC was performed. All retrieved studies were reviewed and qualitatively analyzed. Pooled sensitivity, specificity, positive and negative likelihood ratio (LR+ and LR−) and diagnostic odds ratio (DOR) of 18F-FDG PET or PET/CT in patients with MCC on a per examination-based analysis were calculated. The area under the summary receiver operating characteristic (ROC) curve was calculated to measure the accuracy of 18F-FDG PET or PET/CT in these patients.
RESULTS: Ten studies comprising 329 patients (549 scans) with MCC were included in the qualitative analysis (systematic review) and discussed. The quantitative analysis (meta-analysis) of six selected studies (including 92 patients with MCC) provided the following results on a per examination-based analysis: sensitivity was 90 % (95 % CI 80–96), specificity 98 % (95 % CI 90–100), LR+ 12 (95 % CI 4.3–33.0), LR− 0.15 (95 % CI 0.08–0.28), and DOR 86.8 (95 % CI 23–327). The area under the summary ROC curve was 0.96. No significant statistical heterogeneity between the studies was found.
CONCLUSIONS: In patients with MCC, 18F-FDG PET or PET/CT demonstrated high sensitivity and specificity, being accurate methods in this setting. Nevertheless, the literature focusing on the use of PET and PET/CT in MCC still remains limited. Prospective studies are needed to substantiate the high diagnostic accuracy of these methods in MCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959776     DOI: 10.1007/s40257-013-0040-x

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  18 in total

1.  18F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma.

Authors:  Sonia Mahajan; Christopher A Barker; Audrey Mauguen; Sandra P D'Angelo; Randy Yeh; Neeta Pandit-Taskar
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082

Review 2.  Merkel Cell Carcinoma Therapeutic Update.

Authors:  Nicole M Cassler; Dean Merrill; Christopher K Bichakjian; Isaac Brownell
Journal:  Curr Treat Options Oncol       Date:  2016-07

Review 3.  Modern Approaches for Asymmetric Construction of Carbon-Fluorine Quaternary Stereogenic Centers: Synthetic Challenges and Pharmaceutical Needs.

Authors:  Yi Zhu; Jianlin Han; Jiandong Wang; Norio Shibata; Mikiko Sodeoka; Vadim A Soloshonok; Jaime A S Coelho; F Dean Toste
Journal:  Chem Rev       Date:  2018-04-02       Impact factor: 60.622

Review 4.  Catalytic stereoselective Mannich-type reactions for construction of fluorinated compounds.

Authors:  Minoo Dabiri; Noushin Farajinia Lehi; Reza Mohammadian
Journal:  Mol Divers       Date:  2021-07-06       Impact factor: 2.943

Review 5.  Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Authors:  Valentina Ambrosini; Jolanta Kunikowska; Eric Baudin; Lisa Bodei; Catherine Bouvier; Jaume Capdevila; Marta Cremonesi; Wouter W de Herder; Clarisse Dromain; Massimo Falconi; Melpomeni Fani; Stefano Fanti; Rodney J Hicks; Levent Kabasakal; Gregory Kaltsas; Val Lewington; Silvia Minozzi; Michela Cinquini; Kjell Öberg; Wim J G Oyen; Dermot O'Toole; Marianne Pavel; Philippe Ruszniewski; Aldo Scarpa; Jonathan Strosberg; Anders Sundin; David Taïeb; Irene Virgolini; Damian Wild; Ken Herrmann; James Yao
Journal:  Eur J Cancer       Date:  2021-02-12       Impact factor: 9.162

Review 6.  Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know.

Authors:  Gensuke Akaike; Tomoko Akaike; Shaimaa A Fadl; Kristina Lachance; Paul Nghiem; Fatemeh Behnia
Journal:  Radiographics       Date:  2019 Nov-Dec       Impact factor: 6.312

7.  Merkel cell carcinoma, version 1.2014.

Authors:  Christopher K Bichakjian; Thomas Olencki; Murad Alam; James S Andersen; Daniel Berg; Glen M Bowen; Richard T Cheney; Gregory A Daniels; L Frank Glass; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Daniel D Lydiatt; William H Morrison; Kishwer S Nehal; Kelly C Nelson; Paul Nghiem; Clifford S Perlis; Ashok R Shaha; Wade L Thorstad; Malika Tuli; Marshall M Urist; Timothy S Wang; Andrew E Werchniak; Sandra L Wong; John A Zic; Karin G Hoffmann; Nicole R McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-03-01       Impact factor: 12.693

8.  Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Christopher K Bichakjian; Thomas Olencki; Sumaira Z Aasi; Murad Alam; James S Andersen; Rachel Blitzblau; Glen M Bowen; Carlo M Contreras; Gregory A Daniels; Roy Decker; Jeffrey M Farma; Kris Fisher; Brian Gastman; Karthik Ghosh; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Manisha Loss; Daniel D Lydiatt; Jane Messina; Kishwer S Nehal; Paul Nghiem; Igor Puzanov; Chrysalyne D Schmults; Ashok R Shaha; Valencia Thomas; Yaohui G Xu; John A Zic; Karin G Hoffmann; Anita M Engh
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 12.693

9.  Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-15

Review 10.  Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options.

Authors:  Alok T Saini; Brett A Miles
Journal:  Onco Targets Ther       Date:  2015-08-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.